CTKB
Cytek Biosciences, Inc.
Price Chart
Latest Quote
$3.77
-0.21 (-5.28%)
Current Price
| Previous Close | $3.98 |
| Open | $4.07 |
| Day High | $4.08 |
| Day Low | $3.70 |
| Volume | 15,687,850 |
Stock Information
| Shares Outstanding | 129.14M |
| Total Debt | $27.48M |
| Cash Equivalents | $262.22M |
| Revenue | $204.17M |
| Net Income | $-74.00M |
| Sector | Healthcare |
| Industry | Medical Devices |
| Market Cap | $486.87M |
| EPS (TTM) | $-0.58 |
| Exchange | NMS |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $252.12M |
| Sales | $204.17M |
| Income | $-74.00M |
| Book/sh | $2.54 |
| Cash/sh | $2.03 |
| Employees | 678 |
Financial Ratios
| Quick Ratio | 3.94 |
| Current Ratio | 4.69 |
| Debt/Eq | 8.39 |
Returns & Margins
| ROA | -5.89% |
| ROE | -20.93% |
| Gross Margin | 51.70% |
| Operating Margin | -41.83% |
| Profit Margin | -36.25% |
Ownership
| Insider Ownership | 8.42% |
| Institutional Ownership | 67.59% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | 19.84 |
| P/S | 2.38 |
| P/B | 1.49 |
Analyst Data
| Recommendation | none |
| Target Price | $5.69 |
Technical Indicators
| SMA20 | $4.06 |
| SMA50 | $4.24 |
| SMA200 | $4.48 |
| RSI | 36.71 |
| ATR | 0.2306 |
| Shares Float | 96.54M |
| Short Float | 7.17% |
| Short Ratio | 7.05 |
| Volatility | 1.19 |
| Rel Volume | 8.83 |
Performance History
| Week | -6.22% |
| Month | +5.60% |
| Quarter | -16.41% |
| 6 Months | -19.79% |
| YTD | -23.37% |
| Year | +18.18% |
| 3 Years | -56.47% |
| 10 Years | -79.90% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-18 | $3.77 | 18,260,700 |
| 2026-06-17 | $3.98 | 2,032,600 |
| 2026-06-16 | $4.09 | 1,996,900 |
| 2026-06-15 | $3.93 | 1,551,400 |
| 2026-06-12 | $3.96 | 1,821,800 |
| 2026-06-11 | $4.02 | 2,389,800 |
| 2026-06-10 | $4.05 | 1,069,000 |
| 2026-06-09 | $4.13 | 2,024,300 |
| 2026-06-08 | $4.04 | 1,413,300 |
| 2026-06-05 | $4.09 | 912,400 |
| 2026-06-04 | $4.33 | 706,100 |
| 2026-06-03 | $4.05 | 706,600 |
| 2026-06-02 | $4.19 | 803,400 |
| 2026-06-01 | $4.24 | 774,500 |
| 2026-05-29 | $4.19 | 1,029,900 |
| 2026-05-28 | $4.12 | 887,500 |
| 2026-05-27 | $3.99 | 588,300 |
| 2026-05-26 | $3.97 | 803,300 |
| 2026-05-22 | $4.01 | 853,500 |
| 2026-05-21 | $3.96 | 723,800 |
| 2026-05-20 | $3.77 | 861,000 |
| 2026-05-19 | $3.57 | 968,000 |
About Cytek Biosciences, Inc.
Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitate scientific advances in biomedical research and clinical applications. The company offers Cytek aurora, northern lights systems, and Cytek aurora evo systems delivers cell analysis; Cytek Aurora CS System, a cellular complexity to perform additional downstream genomic and proteomic studies using phenotyping approaches; enhanced small particle detection; Cytek amnis imagestream imaging flow cytometers; Cytek guava muse cell analyzers; Cytek muse micro cell analyzers; Cytek guava easyCyte flow cytometers; and Cytek orion reagent cocktail preparation systems. It also provides reagents and kits, including cFluor reagents that are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments. In addition, the company offers automated micro-sampling system and automated sample loader system, an automated loaders designed to integrate seamlessly into the Cytek aurora and northern lights systems; SpectroFlo software that provides intuitive workflow from quality control to data analysis for Cytek aurora, northern lights, and Cytek aurora evo systems; and customer support tools. Further, it provides conventional flow and image-based flow cytometry instrumentation and related products and services under the Amnis and Guava brand names. The company serves pharmaceutical and biopharma companies, academic research centers, and contract research organizations. It distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific regions; and through distributors or sales agents in Europe, Latin America, and the Middle East countries. The company was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015. Cytek Biosciences, Inc. was founded in 1992 and is headquartered in Fremont, California.
đ° Latest News
Cytek Biosciences (CTKB) Stock Sees Fair Value Falls After Analysts Cut Targets
Simply Wall St. âĸ 2026-06-17T07:14:38Z
Promising Penny Stocks To Consider In June 2026
Simply Wall St. âĸ 2026-06-01T18:05:30Z
Prenetics Starts Partnership with Jay Shetty as IM8 Global Ambassador & Shareholder
IPO-Edge.com âĸ 2026-05-20T20:51:00Z
Cytek (CTKB) Q1 2026 Earnings Call Transcript
Motley Fool âĸ 2026-05-08T14:32:37Z
Cytek Biosciences, Inc. Q1 2026 Earnings Call Summary
Moby âĸ 2026-05-08T12:30:00Z
Cytek Biosciences, Inc. (CTKB) Reports Q1 Loss, Beats Revenue Estimates
Zacks âĸ 2026-05-07T23:05:25Z
Cytek Biosciences Q1 Earnings Call Highlights
MarketBeat âĸ 2026-05-07T21:39:37Z
AbCellera Biologics Among 3 Promising Penny Stocks
Simply Wall St. âĸ 2026-05-01T12:05:37Z
Cytek Biosciences (CTKB) Inspiring Confidence With Aurora CS System Updates
Insider Monkey âĸ 2026-04-14T05:29:28Z
Nautilus Biotechnology And 2 Other Compelling Penny Stocks For Your Watchlist
Simply Wall St. âĸ 2026-03-25T12:05:06Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $97,033,000 | $89,347,000 | $83,589,000 | $63,062,000 |
| Cost Of Revenue | $97,033,000 | $89,347,000 | $83,589,000 | $63,062,000 |
| Total Revenue | $201,493,000 | $200,453,000 | $193,015,000 | $164,036,000 |
| Operating Revenue | $201,493,000 | $200,453,000 | $193,015,000 | $164,036,000 |
| Expenses | ||||
| Interest Expense | $474,000 | - | $2,071,000 | $2,573,000 |
| Total Expenses | $241,877,000 | $220,976,000 | $220,860,000 | $165,840,000 |
| Other Income Expense | $8,801,000 | $4,463,000 | $7,794,000 | $1,018,000 |
| Other Non Operating Income Expenses | $8,801,000 | $4,463,000 | $7,794,000 | $1,018,000 |
| Net Non Operating Interest Income Expense | $1,742,000 | $10,360,000 | $4,342,000 | $2,046,000 |
| Interest Expense Non Operating | $474,000 | - | $2,071,000 | $2,573,000 |
| Operating Expense | $144,844,000 | $131,629,000 | $137,271,000 | $102,778,000 |
| Selling And Marketing Expense | $49,440,000 | $49,114,000 | $49,148,000 | $33,230,000 |
| General And Administrative Expense | $58,936,000 | $43,113,000 | $43,972,000 | $34,690,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-66,539,000 | $-6,020,000 | $-12,148,000 | $2,576,000 |
| Net Interest Income | $1,742,000 | $10,360,000 | $4,342,000 | $2,046,000 |
| Interest Income | $2,216,000 | $10,360,000 | $6,413,000 | $4,619,000 |
| Normalized Income | $-66,539,000 | $-6,020,000 | $-12,148,000 | $2,576,000 |
| Net Income From Continuing And Discontinued Operation | $-66,539,000 | $-6,020,000 | $-12,148,000 | $2,576,000 |
| Total Operating Income As Reported | $-40,384,000 | $-20,523,000 | $-27,845,000 | $-1,804,000 |
| Net Income Common Stockholders | $-66,539,000 | $-6,020,000 | $-12,148,000 | $2,576,000 |
| Net Income | $-66,539,000 | $-6,020,000 | $-12,148,000 | $2,576,000 |
| Net Income Including Noncontrolling Interests | $-66,539,000 | $-6,020,000 | $-12,148,000 | $2,484,000 |
| Net Income Continuous Operations | $-66,539,000 | $-6,020,000 | $-12,148,000 | $2,484,000 |
| Pretax Income | $-29,841,000 | $-5,700,000 | $-15,709,000 | $1,260,000 |
| Interest Income Non Operating | $2,216,000 | $10,360,000 | $6,413,000 | $4,619,000 |
| Operating Income | $-40,384,000 | $-20,523,000 | $-27,845,000 | $-1,804,000 |
| Gross Profit | $104,460,000 | $111,106,000 | $109,426,000 | $100,974,000 |
| Per Share | ||||
| Diluted EPS | $-0.52 | $-0.05 | $-0.09 | $0.02 |
| Basic EPS | $-0.52 | $-0.05 | $-0.09 | $0.02 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-17,392,000 | $-10,033,000 | $-4,408,000 | $9,492,000 |
| Reconciled Depreciation | $11,975,000 | $10,490,000 | $9,230,000 | $5,659,000 |
| EBITDA (Bullshit earnings) | $-17,392,000 | $-10,033,000 | $-4,408,000 | $9,492,000 |
| EBIT | $-29,367,000 | $-20,523,000 | $-13,638,000 | $3,833,000 |
| Diluted Average Shares | $127,745,939 | $130,611,330 | $130,714,906 | $138,562,111 |
| Basic Average Shares | $127,745,939 | $130,611,330 | $130,714,906 | $134,510,831 |
| Diluted NI Availto Com Stockholders | $-66,539,000 | $-6,020,000 | $-12,148,000 | $2,576,000 |
| Minority Interests | $0 | $0 | $0 | $92,000 |
| Tax Provision | $36,698,000 | $320,000 | $-3,561,000 | $-1,224,000 |
| Research And Development | $36,468,000 | $39,402,000 | $44,151,000 | $34,858,000 |
| Selling General And Administration | $108,376,000 | $92,227,000 | $93,120,000 | $67,920,000 |
| Other Gand A | $58,936,000 | $43,113,000 | $43,972,000 | $34,690,000 |
| Otherunder Preferred Stock Dividend | - | - | $0 | $0 |
Fetched: 2026-06-18
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $308,221,000 | $358,946,000 | $353,797,000 | $410,820,000 |
| Total Assets | $461,542,000 | $499,500,000 | $494,457,000 | $519,476,000 |
| Total Non Current Assets | $69,546,000 | $103,054,000 | $102,397,000 | $65,456,000 |
| Other Non Current Assets | $6,704,000 | $4,759,000 | $3,385,000 | $2,957,000 |
| Non Current Deferred Assets | $0 | $33,374,000 | $30,487,000 | $20,459,000 |
| Non Current Deferred Taxes Assets | $0 | $33,374,000 | $30,487,000 | $20,459,000 |
| Goodwill And Other Intangible Assets | $33,518,000 | $36,791,000 | $39,267,000 | $14,475,000 |
| Other Intangible Assets | $16,821,000 | $20,128,000 | $23,084,000 | $4,331,000 |
| Current Assets | $391,996,000 | $396,446,000 | $392,060,000 | $454,020,000 |
| Other Current Assets | $2,977,000 | $1,943,000 | $2,230,000 | $3,796,000 |
| Restricted Cash | $0 | $29,000 | $331,000 | $2,899,000 |
| Prepaid Assets | $6,935,000 | $12,132,000 | $10,092,000 | $7,147,000 |
| Inventory | $48,428,000 | $43,893,000 | $60,877,000 | $48,154,000 |
| Receivables | $72,127,000 | $60,588,000 | $56,120,000 | $50,875,000 |
| Other Receivables | $4,208,000 | - | - | - |
| Taxes Receivable | $5,410,000 | $0 | $192,000 | $2,011,000 |
| Accounts Receivable | $62,509,000 | $60,588,000 | $55,928,000 | $48,864,000 |
| Cash Cash Equivalents And Short Term Investments | $261,529,000 | $277,861,000 | $262,410,000 | $341,149,000 |
| Cash And Cash Equivalents | $90,853,000 | $98,716,000 | $167,299,000 | $296,601,000 |
| Cash Equivalents | $61,870,000 | $66,465,000 | $144,892,000 | $173,230,000 |
| Cash Financial | $28,983,000 | $32,251,000 | $22,407,000 | $123,371,000 |
| Allowance For Doubtful Accounts Receivable | - | $-310,000 | $-372,000 | $-102,000 |
| Gross Accounts Receivable | - | $60,898,000 | $56,300,000 | $48,966,000 |
| Debt | ||||
| Total Debt | $23,743,000 | $17,016,000 | $14,136,000 | $18,094,000 |
| Long Term Debt And Capital Lease Obligation | $14,567,000 | $8,602,000 | $11,127,000 | $14,583,000 |
| Long Term Debt | $525,000 | $1,050,000 | $1,648,000 | $2,271,000 |
| Current Debt And Capital Lease Obligation | $9,176,000 | $8,414,000 | $3,009,000 | $3,511,000 |
| Current Debt | $6,296,000 | $4,658,000 | $565,000 | $580,000 |
| Other Current Borrowings | $6,296,000 | $4,658,000 | $565,000 | $580,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $119,803,000 | $103,763,000 | $101,393,000 | $93,930,000 |
| Total Non Current Liabilities Net Minority Interest | $41,999,000 | $36,100,000 | $45,167,000 | $44,890,000 |
| Other Non Current Liabilities | $9,093,000 | $11,400,000 | $18,908,000 | $17,183,000 |
| Non Current Deferred Liabilities | $18,339,000 | $16,098,000 | $15,132,000 | $13,124,000 |
| Current Liabilities | $77,804,000 | $67,663,000 | $56,226,000 | $49,040,000 |
| Other Current Liabilities | $2,946,000 | $2,108,000 | $2,957,000 | $3,390,000 |
| Current Deferred Liabilities | $29,572,000 | $26,610,000 | $24,133,000 | $14,541,000 |
| Payables And Accrued Expenses | $20,918,000 | $15,766,000 | $12,379,000 | $13,687,000 |
| Payables | $12,693,000 | $9,088,000 | $6,092,000 | $6,472,000 |
| Total Tax Payable | $6,283,000 | $3,559,000 | $3,060,000 | $1,667,000 |
| Income Tax Payable | $3,067,000 | $1,516,000 | $1,297,000 | $246,000 |
| Accounts Payable | $6,410,000 | $5,529,000 | $3,032,000 | $4,805,000 |
| Equity | ||||
| Common Stock Equity | $341,739,000 | $395,737,000 | $393,064,000 | $425,295,000 |
| Total Equity Gross Minority Interest | $341,739,000 | $395,737,000 | $393,064,000 | $425,546,000 |
| Stockholders Equity | $341,739,000 | $395,737,000 | $393,064,000 | $425,295,000 |
| Gains Losses Not Affecting Retained Earnings | $2,241,000 | $16,000 | $-1,275,000 | $-697,000 |
| Other Equity Adjustments | $2,241,000 | $16,000 | $-1,275,000 | $-697,000 |
| Retained Earnings | $-101,738,000 | $-35,199,000 | $-29,178,000 | $-17,030,000 |
| Preferred Securities Outside Stock Equity | - | - | - | - |
| Other | ||||
| Ordinary Shares Number | $128,550,136 | $129,205,901 | $130,714,906 | $135,365,381 |
| Share Issued | $128,550,136 | $129,205,901 | $130,714,906 | $135,365,381 |
| Tangible Book Value | $308,221,000 | $358,946,000 | $353,797,000 | $410,820,000 |
| Invested Capital | $348,560,000 | $401,445,000 | $395,277,000 | $428,146,000 |
| Working Capital | $314,192,000 | $328,783,000 | $335,834,000 | $404,980,000 |
| Capital Lease Obligations | $16,922,000 | $11,308,000 | $11,923,000 | $15,243,000 |
| Total Capitalization | $342,264,000 | $396,787,000 | $394,712,000 | $427,566,000 |
| Minority Interest | $0 | $0 | $0 | $251,000 |
| Additional Paid In Capital | $441,107,000 | $430,791,000 | $423,386,000 | $442,887,000 |
| Capital Stock | $129,000 | $129,000 | $131,000 | $135,000 |
| Common Stock | $129,000 | $129,000 | $131,000 | $135,000 |
| Non Current Deferred Revenue | $18,339,000 | $16,098,000 | $15,132,000 | $13,124,000 |
| Long Term Capital Lease Obligation | $14,042,000 | $7,552,000 | $9,479,000 | $12,312,000 |
| Current Deferred Revenue | $29,572,000 | $26,610,000 | $24,133,000 | $14,541,000 |
| Current Capital Lease Obligation | $2,880,000 | $3,756,000 | $2,444,000 | $2,931,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $15,192,000 | $14,765,000 | $13,748,000 | $13,911,000 |
| Current Accrued Expenses | $8,225,000 | $6,678,000 | $6,287,000 | $7,215,000 |
| Goodwill | $16,697,000 | $16,663,000 | $16,183,000 | $10,144,000 |
| Net PPE | $29,324,000 | $28,130,000 | $29,258,000 | $27,565,000 |
| Accumulated Depreciation | $-12,134,000 | $-8,714,000 | $-5,920,000 | $-3,159,000 |
| Gross PPE | $41,458,000 | $36,844,000 | $35,178,000 | $30,724,000 |
| Leases | $3,518,000 | $3,224,000 | $3,623,000 | $3,481,000 |
| Construction In Progress | $1,417,000 | $357,000 | $256,000 | $178,000 |
| Other Properties | $23,192,000 | $21,807,000 | $20,325,000 | $18,660,000 |
| Machinery Furniture Equipment | $5,409,000 | $3,693,000 | $3,321,000 | $2,852,000 |
| Buildings And Improvements | $7,922,000 | $7,763,000 | $7,653,000 | $5,553,000 |
| Properties | $0 | $0 | $0 | $0 |
| Finished Goods | $11,455,000 | $14,834,000 | $14,705,000 | $16,332,000 |
| Work In Process | $16,531,000 | $6,488,000 | $10,454,000 | $4,897,000 |
| Raw Materials | $20,442,000 | $22,571,000 | $35,718,000 | $26,925,000 |
| Other Short Term Investments | $170,676,000 | $179,145,000 | $95,111,000 | $44,548,000 |
| Line Of Credit | - | - | - | - |
Fetched: 2026-06-18
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-8,876,000 | $21,650,000 | $454,000 | $-22,099,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-4,686,000 | $25,379,000 | $5,281,000 | $-12,231,000 |
| Cash Flow From Continuing Operating Activities | $-4,686,000 | $25,379,000 | $5,281,000 | $-12,231,000 |
| Operating Gains Losses | $-5,258,000 | $-5,156,000 | $-6,654,000 | $-77,000 |
| Investing Activities | ||||
| Capital Expenditure | $-4,190,000 | $-3,729,000 | $-4,827,000 | $-9,868,000 |
| Investing Cash Flow | $10,117,000 | $-82,974,000 | $-93,894,000 | $-55,909,000 |
| Cash Flow From Continuing Investing Activities | $10,118,000 | $-82,974,000 | $-93,894,000 | $-55,909,000 |
| Net Other Investing Changes | $-1,000 | - | - | - |
| Financing Activities | ||||
| Repurchase Of Capital Stock | $-15,074,000 | $-21,611,000 | $-44,151,000 | $0 |
| Financing Cash Flow | $-13,432,000 | $-15,822,000 | $-41,812,000 | $5,513,000 |
| Cash Flow From Continuing Financing Activities | $-13,433,000 | $-15,822,000 | $-41,812,000 | $5,513,000 |
| Net Other Financing Charges | $-669,000 | $-554,000 | $-419,000 | $-209,000 |
| Net Common Stock Issuance | $-15,074,000 | $-21,611,000 | $-44,151,000 | $0 |
| Issuance Of Capital Stock | - | - | $0 | $0 |
| Common Stock Issuance | - | - | $0 | $0 |
| Net Preferred Stock Issuance | - | - | - | $0 |
| Preferred Stock Issuance | - | - | - | $0 |
| Other | ||||
| Repayment Of Debt | $-4,745,000 | $-557,000 | $-565,000 | $-50,000 |
| Issuance Of Debt | $5,582,000 | $4,181,000 | $0 | $2,983,000 |
| Income Tax Paid Supplemental Data | $2,159,000 | $3,828,000 | $5,305,000 | $10,390,000 |
| End Cash Position | $90,853,000 | $98,745,000 | $167,630,000 | $299,500,000 |
| Beginning Cash Position | $98,745,000 | $167,630,000 | $299,500,000 | $364,618,000 |
| Effect Of Exchange Rate Changes | $109,000 | $4,532,000 | $-1,445,000 | $-2,491,000 |
| Changes In Cash | $-8,001,000 | $-73,417,000 | $-130,425,000 | $-62,627,000 |
| Proceeds From Stock Option Exercised | $1,474,000 | $2,719,000 | $3,323,000 | $2,789,000 |
| Common Stock Payments | $-15,074,000 | $-21,611,000 | $-44,151,000 | $0 |
| Net Issuance Payments Of Debt | $837,000 | $3,624,000 | $-565,000 | $2,933,000 |
| Net Short Term Debt Issuance | $5,582,000 | $4,181,000 | $0 | - |
| Short Term Debt Issuance | $5,582,000 | $4,181,000 | $0 | - |
| Net Long Term Debt Issuance | $837,000 | $3,624,000 | $-565,000 | $2,933,000 |
| Long Term Debt Payments | $-4,745,000 | $-557,000 | $-565,000 | $-50,000 |
| Long Term Debt Issuance | $5,582,000 | $4,181,000 | $0 | $2,983,000 |
| Net Investment Purchase And Sale | $14,056,000 | $-79,062,000 | $-43,935,000 | $-46,041,000 |
| Sale Of Investment | $292,211,000 | $195,000,000 | $132,000,000 | $0 |
| Purchase Of Investment | $-278,155,000 | $-274,062,000 | $-175,935,000 | $-46,041,000 |
| Net Business Purchase And Sale | $0 | $-471,000 | $-45,132,000 | $0 |
| Purchase Of Business | $0 | $-471,000 | $-45,132,000 | $0 |
| Net Intangibles Purchase And Sale | $-106,000 | $-204,000 | $-179,000 | $-120,000 |
| Purchase Of Intangibles | $-106,000 | $-204,000 | $-179,000 | $-120,000 |
| Net PPE Purchase And Sale | $-3,832,000 | $-3,237,000 | $-4,648,000 | $-9,748,000 |
| Sale Of PPE | $252,000 | $288,000 | $0 | $0 |
| Purchase Of PPE | $-4,084,000 | $-3,525,000 | $-4,648,000 | $-9,748,000 |
| Change In Working Capital | $-4,794,000 | $7,713,000 | $-10,509,000 | $-39,928,000 |
| Change In Other Working Capital | $3,601,000 | $3,737,000 | $6,520,000 | $9,411,000 |
| Change In Other Current Liabilities | $-5,279,000 | $-4,307,000 | $-3,413,000 | $-1,912,000 |
| Change In Payables And Accrued Expense | $4,418,000 | $1,765,000 | $-1,055,000 | $9,332,000 |
| Change In Accrued Expense | $3,970,000 | $-817,000 | $729,000 | $7,470,000 |
| Change In Payable | $448,000 | $2,582,000 | $-1,784,000 | $1,862,000 |
| Change In Account Payable | $448,000 | $2,582,000 | $-1,784,000 | $1,862,000 |
| Change In Prepaid Assets | $-2,658,000 | $-2,809,000 | $-9,515,000 | $-19,362,000 |
| Change In Inventory | $-5,244,000 | $14,755,000 | $4,286,000 | $-17,653,000 |
| Change In Receivables | $368,000 | $-5,428,000 | $-7,332,000 | $-19,744,000 |
| Changes In Account Receivables | $368,000 | $-5,428,000 | $-7,332,000 | $-19,744,000 |
| Other Non Cash Items | $-328,000 | $-7,192,000 | $1,577,000 | $2,178,000 |
| Stock Based Compensation | $24,585,000 | $26,848,000 | $22,048,000 | $16,595,000 |
| Provisionand Write Offof Assets | $2,116,000 | $1,582,000 | $1,737,000 | $858,000 |
| Deferred Tax | $33,557,000 | $-2,886,000 | $0 | $0 |
| Deferred Income Tax | $33,557,000 | $-2,886,000 | $0 | $0 |
| Depreciation Amortization Depletion | $11,975,000 | $10,490,000 | $9,230,000 | $5,659,000 |
| Depreciation And Amortization | $11,975,000 | $10,490,000 | $9,230,000 | $5,659,000 |
| Depreciation | $11,975,000 | $10,490,000 | $9,230,000 | $5,659,000 |
| Gain Loss On Investment Securities | $-5,673,000 | $-5,211,000 | $-6,661,000 | $-77,000 |
| Gain Loss On Sale Of PPE | $415,000 | $55,000 | $7,000 | $0 |
| Net Income From Continuing Operations | $-66,539,000 | $-6,020,000 | $-12,148,000 | $2,484,000 |
| Earnings Losses From Equity Investments | - | - | $0 | $0 |
| Sale Of Business | - | - | - | $0 |
| Amortization Of Securities | - | - | - | $-77,000 |
Fetched: 2026-06-18